Doxorubicin Liposomal bulk supplier for pharma manufacturers

Doxorubicin Liposomal Suppliers & Bulk Manufacturers

Available Forms: Liposomal Injection (

Available Strengths: 20 mg/10 mL (2 mg/mL), 50 mg/25 mL (2 mg/mL)

Reference Brands: Doxil® , Caelyx® (EU & US)

Doxorubicin Liposomal, sold as Doxil® (US) and Caelyx® (EU), is used for breast cancer, ovarian cancer, Kaposi’s sarcoma, and multiple myeloma. The liposomal formulation targets tumors more effectively, reducing systemic toxicity. Available in 20 mg/10 mL and 50 mg/25 mL concentrations, it is provided in single-use vials. Trusted by oncologists, it offers effective cancer treatment with minimized side effects in US and EU markets.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description: Doxorubicin Liposomal, marketed as Doxil® (US) and Caelyx® (EU), is a chemotherapy agent used to treat breast cancer, ovarian cancer, Kaposi’s sarcoma, and multiple myeloma. Its liposomal formulation encapsulates the doxorubicin drug, allowing for more targeted delivery and reduced systemic toxicity compared to conventional doxorubicin. Available in 20 mg/10 mL and 50 mg/25 mL concentrations, it is supplied in single-use vials for oncology treatment. Sourced from GMP-compliant manufacturers, Doxorubicin Liposomal offers effective treatment for cancer patients while minimizing side effects, making it a trusted choice for healthcare providers in US and EU markets.

Doxorubicin Liposomal — third party manufacturing & bulk supply

Doxorubicin Liposomal is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Doxorubicin Liposomal is supplied as Liposomal Injection ( — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Doxorubicin Liposomal listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Doxorubicin Liposomal →

Back to Listing

Frequently Asked Questions

Doxorubicin Liposomal is listed as Liposomal Injection ( in 20 mg/10 mL (2 mg/mL), 50 mg/25 mL (2 mg/mL). Further strengths and pack presentations are confirmed with the manufacturer at RFQ stage.

Doxorubicin Liposomal is referenced against Doxil® , Caelyx® (EU & US). Reference brands are shown for identification only and remain the property of their respective trademark owners.